Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-064267
Filing Date
2026-02-23
Accepted
2026-02-23 17:02:12
Documents
107
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K axsm-20251231.htm   iXBRL 10-K 3957180
2 EX-21.1 axsm-ex21_1.htm EX-21.1 7301
3 EX-23.1 axsm-ex23_1.htm EX-23.1 5556
4 EX-31.1 axsm-ex31_1.htm EX-31.1 19110
5 EX-31.2 axsm-ex31_2.htm EX-31.2 18643
6 EX-32.1 axsm-ex32_1.htm EX-32.1 7363
7 EX-32.2 axsm-ex32_2.htm EX-32.2 7362
8 GRAPHIC img129829423_0.gif GRAPHIC 1067008
9 GRAPHIC img129829423_1.gif GRAPHIC 141386
  Complete submission text file 0001193125-26-064267.txt   19600621

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT axsm-20251231.xsd EX-101.SCH 2222466
110 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20251231_htm.xml XML 3144408
Mailing Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007
Business Address ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37635 | Film No.: 26666227
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)